These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24326004)

  • 1. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
    Davis SN; Wei W; Garg S
    Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
    Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
    Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.
    Korytkowski M; Bell D; Jacobsen C; Suwannasari R;
    Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes.
    Warren ML; Brod M; Håkan-Bloch J; Sparre T; Chaykin LB
    Curr Med Res Opin; 2019 Sep; 35(9):1623-1629. PubMed ID: 30974973
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P; Jérémie W; Buysschaert M
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
    Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
    Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preference for a new prefilled insulin pen compared with the original pen.
    Garg S; Bailey T; DeLuzio T; Pollom D
    Curr Med Res Opin; 2011 Dec; 27(12):2323-33. PubMed ID: 21988614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
    Asche CV; Luo W; Aagren M
    Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of simplicity, convenience, safety, and cost-effectiveness between use of insulin pen devices and disposable plastic syringes by patients with type 2 diabetes mellitus: a cross-sectional study from Bangladesh.
    Kamrul-Hasan ABM; Hannan MA; Alam MS; Rahman MM; Asaduzzaman M; Mustari M; Paul AK; Kabir ML; Chowdhury SR; Talukder SK; Sarkar S; Hannan MA; Islam MR; Iftekhar MH; Robel MAB; Selim S
    BMC Endocr Disord; 2023 Feb; 23(1):37. PubMed ID: 36782190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain.
    Riebenfeld D; Spirk D; Mathis A; Villiger L; Gerber PA; Gasser UE; Lehmann R
    Swiss Med Wkly; 2015; 145():w14114. PubMed ID: 25741640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.